1. Home
  2. PRTA vs SUPV Comparison

PRTA vs SUPV Comparison

Compare PRTA & SUPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • SUPV
  • Stock Information
  • Founded
  • PRTA 2012
  • SUPV 1887
  • Country
  • PRTA Ireland
  • SUPV Argentina
  • Employees
  • PRTA N/A
  • SUPV N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • SUPV Commercial Banks
  • Sector
  • PRTA Health Care
  • SUPV Finance
  • Exchange
  • PRTA Nasdaq
  • SUPV Nasdaq
  • Market Cap
  • PRTA 802.8M
  • SUPV 908.5M
  • IPO Year
  • PRTA N/A
  • SUPV 2016
  • Fundamental
  • Price
  • PRTA $13.41
  • SUPV $15.70
  • Analyst Decision
  • PRTA Buy
  • SUPV
  • Analyst Count
  • PRTA 7
  • SUPV 0
  • Target Price
  • PRTA $57.67
  • SUPV N/A
  • AVG Volume (30 Days)
  • PRTA 448.2K
  • SUPV 1.4M
  • Earning Date
  • PRTA 11-12-2024
  • SUPV 11-25-2024
  • Dividend Yield
  • PRTA N/A
  • SUPV 1.09%
  • EPS Growth
  • PRTA N/A
  • SUPV 67.85
  • EPS
  • PRTA N/A
  • SUPV 0.19
  • Revenue
  • PRTA $133,350,000.00
  • SUPV $435,663,160.00
  • Revenue This Year
  • PRTA $46.28
  • SUPV N/A
  • Revenue Next Year
  • PRTA N/A
  • SUPV N/A
  • P/E Ratio
  • PRTA N/A
  • SUPV $17.21
  • Revenue Growth
  • PRTA N/A
  • SUPV N/A
  • 52 Week Low
  • PRTA $12.31
  • SUPV $3.33
  • 52 Week High
  • PRTA $41.55
  • SUPV $16.27
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 43.50
  • SUPV 84.84
  • Support Level
  • PRTA $12.31
  • SUPV $11.77
  • Resistance Level
  • PRTA $14.28
  • SUPV $16.27
  • Average True Range (ATR)
  • PRTA 0.98
  • SUPV 0.84
  • MACD
  • PRTA 0.00
  • SUPV 0.29
  • Stochastic Oscillator
  • PRTA 33.73
  • SUPV 89.61

About PRTA Prothena Corporation plc

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, Asset Management, and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.

Share on Social Networks: